In this issue of the European Journal of Internal Medicine, Carlos Baeza-Delgado et al. present a compelling real-world analysis utilizing a large electronic health record database [1]. The study evaluates the prevalence of elevated non-HDL-C levels in a lipid-lowering therapy-naive general population, while assessing both its baseline association with cardiometabolic diseases and its capacity to predict future metabolic conditions.
